Document Detail

Molecular targeted therapies for renal cell carcinoma.
MedLine Citation:
PMID:  18163945     Owner:  NLM     Status:  MEDLINE    
New advances in technology to directly target specific molecular events in the proliferation of cancer have led to promising results in renal cell carcinoma. Response rates in excess of 70% and complete responses in advanced (metastatic) renal cell carcinoma have caused a change in the paradigm of treatment from immunotherapy. Toxicities are significant, but manageable and pushing the toxicity to tolerability may increase the response rate.
Sam D Graham; Mary Elizabeth Warden; Jeffrey Lou
Related Documents :
11381825 - A survival analysis of metastatic breast cancer in pakistani patients.
22276005 - Male breast cancer: a review.
12908795 - Breast cancer metastatic to the choroid in a male patient: case report.
23860775 - Myc overexpression and poor prognosis in sporadic breast cancer with brca1 deficiency.
435005 - Tamoxifen in advanced male breast cancer.
7986145 - Clinical implications of cervical lymph node metastasis patterns in thoracic esophageal...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of urology     Volume:  14 Suppl 1     ISSN:  1195-9479     ISO Abbreviation:  Can J Urol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-31     Completed Date:  2008-03-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9515842     Medline TA:  Can J Urol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  48-52     Citation Subset:  IM    
Urologic Specialists of Virginia, Richmond, VA 23225, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Immunotherapy / methods*
Kidney Neoplasms / drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current management of small renal masses.
Next Document:  Medical management of benign prostatic hypertrophy.